Fusion Pharmaceuticals In... (FUSN)
NASDAQ: FUSN
· Real-Time Price · USD
21.55
0.03 (0.14%)
At close: Jun 03, 2024, 8:00 PM
0.14% (1D)
| Bid | n/a |
| Market Cap | 1.83B |
| Revenue (ttm) | 35.68M |
| Net Income (ttm) | -104.28M |
| EPS (ttm) | -1.4 |
| PE Ratio (ttm) | -15.392857142857142 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 6,081,107 |
| Avg. Volume (20D) | 1,965,984 |
| Open | 21.55 |
| Previous Close | 21.52 |
| Day's Range | 21.48 - 21.58 |
| 52-Week Range | 2.31 - 21.60 |
| Beta | -0.69 |
About FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 th...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 101
Stock Exchange NASDAQ
Ticker Symbol FUSN
Website https://fusionpharma.com
2 months ago · investopedia.com
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer PipelineAstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer.